Many patients with metastatic castration-resistant prostate cancer are not receiving bone-modifying agents, despite guideline endorsement.
Figure 3: Immunohistochemistry (IHC) and Immunofluorescence (IF) analysis of MD2 expression and immune cell infiltration in prostate cancer tissues. (Upper panel) Representative IF images showing ...
The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial Radium-223 is an α-emitting ...
Bone metastases represent a common and debilitating stage in the progression of many solid tumours, notably breast, prostate and lung cancers. Tumour cells that home to the skeleton disrupt the normal ...
Researchers at Baylor College of Medicine and collaborating institutions have developed a method that reveals the cellular makeup of tissues that support metastatic cancer growth, which is the primary ...
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study The classification of patients with prostate cancer, based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results